Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Anniston, Alabama 36207


An international, multi-centre, prospective three arm parallel-group, phase II proof of concept study comparing the efficacy and safety of two dosage regimens (BID 7 days and TID 7 days) of TD1414 2% cream and one dosage regimen (BID 7 days) of Bactroban® (mupirocin) 2% cream in adults and children down to 2 years of age with impetigo or SITL. Furthermore an evaluation of the pharmacokinetics of TD1414 2% cream TID for 7 days will be performed. A total of 664 patients will be enrolled in a stepwise manner according to age groups starting with the oldest age group.


Inclusion Criteria: - Signed and dated informed consent from patient and/or legally acceptable representative has been obtained - Outpatients of any sex or ethnic origin - Patients >= 2 years of age (depending on study step) - Patients must be suffering from primary bullous/non-bullous impetigo or SITL Exclusion Criteria: - Presence of skin diseases at or near the investigational area - Immunosuppressed state or other serious systemic disease - Signs and/or symptoms of systemic infection - Presence of skin infection/disorder not amenable to topical antibacterial treatment only - Presence of secondarily-infected animal/human bite - Presence of secondarily infected burnwound - Topical or systemic use of medicinal or other products before or during the study which in the investigators opinion could confound the evaluation of the effect of the study drugs - Known or suspected hypersensitivity to TD1414 or any of the excipients in the TD1414 2% cream - Known or suspected hypersensitivity to mupirocin or any of the excipients in the Bactroban® (mupirocin) 2% cream - Participation in any other investigational drug study or use of (an) investigational drug(s) within the 30 days or 5 half-lives (whichever is longer) prior to randomisation - Patients previously enrolled/randomised in this study - Abnormal ECG at baseline though the PR interval may be up to 220 ms, the QRS interval up to 110 ms and the QTc interval up to 450 ms



Primary Contact:

Principal Investigator
Almena L Free, MD
Anniston Medical Clinic

Backup Contact:


Location Contact:

Anniston, Alabama 36207
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source: ClinicalTrials.gov

Date Processed: February 04, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.